The Barcelonaβeta Brain Research Center (BBRC) has been chosen as a participating center in the multicenter, prospective, non-interventional study EAPP (Elecsys® Amyloid Plasma Panel) by Roche Diagnostics. The aim of the trial is to demonstrate the clinical performance of the EAPP test, a test to facilitate early diagnosis of Alzheimer's. This tool, based on a blood test, would make possible to identify the probability of amyloid pathology in people with subjective memory complaints and to determine if they should undergo further evaluations and tests that can confirm the diagnosis, such as lumbar puncture or positron emission tomography. This month of July the first visit to the research center of the Pasqual Maragall Foundation took place. EAPP is also being tested in other European countries such as Germany, Austria, Denmark and the United Kingdom.
This clinical trial, which is scheduled to last for one year, along with a follow-up period of three months, will involve people between the ages of 55 and 80 with subjective memory complaints or objective cognitive impairment who are being evaluated for the diagnosis of Alzheimer's disease or similar.